Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 4 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.


Player Avatar zzlangerhans (99.85) Submitted: 3/24/2010 8:23:29 PM : Underperform Start Price: $1.52 AMRN Score: -475.90

Hemispheryx has Ampligen and Amarin has ethyl-EPA. Neither of these companies will let repeated trial failures prevent them from flogging their single pipeline products in new studies for new indications, relying on a never-ending supply of naive retail investors to suck up diluted equity. Amarin's MARINE and ANCHOR phase III trials of ethyl-EPA in hypertryglyceridemia won't be completed until 2011, and will likely turn out about as well as the phase III trials in dementia. In baby biotech, it's anyone's guess how high Amarin's share price might go awaiting those trial results. What seems much more likely is that Amarin will be sub 0.5 and headed for yet another reverse split once those results are in.

Member Avatar peterod (84.88) Submitted: 6/20/2012 3:21:15 PM
Recs: 1

you've got some conviction.....

Featured Broker Partners